Raptor Pharmaceutical (RPTP) 8.44 $RPTP
Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline Review, H2 2014
M2 - Mon Dec 08, 3:23AM CST
Research and Markets (http://www.researchandmarkets.com/research/48lh7t/non_alcoholic) has announced the addition of the "Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Non Alcoholic Fatty Liver Disease (NAFLD), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Non Alcoholic Fatty Liver Disease (NAFLD) and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Non Alcoholic Fatty Liver Disease (NAFLD) - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Non Alcoholic Fatty Liver Disease (NAFLD) pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope Companies Mentioned: - F. Hoffmann-La Roche - Merck & Co - Novartis - Daewoong Pharmaceutical - Orchid Chemicals & Pharmaceuticals - Phynova Group - Raptor Pharmaceuticals - Phenex Pharmaceuticals - Metabolic Solutions Development - Zafgen - Verva Pharmaceuticals - Galmed International - TCM Biotech International For more information visit http://www.researchandmarkets.com/research/48..._alcoholic
RPTP: 8.44 (+0.22), MRK: 57.72 (-1.62), NVS: 93.52 (-0.82)
Raptor Pharmaceutical Corp. Is An Investment With Significant Upside IN 2015
Clinically Sound Investor - at Seeking Alpha - Thu Dec 04, 8:57AM CST
RPTP: 8.44 (+0.22)
Parkinson's Disease - Pipeline Review, H2 2014
M2 - Tue Dec 02, 5:55AM CST
Research and Markets (http://www.researchandmarkets.com/research/7k9xvt/parkinsons) has announced the addition of the "Parkinson's Disease - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Parkinson's Disease, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Parkinson's Disease - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Parkinson's Disease pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: 169 companies are cited in this text including: - Amicus Therapeutics, Inc. - AstraZeneca PLC - Bial - Portela & Ca, S.A. - Calico LLC - Cardax Pharmaceuticals, Inc. - Edison Pharmaceuticals, Inc. - GlaxoSmithKline plc - GliaCure Inc. - H. Lundbeck A/S - Io Therapeutics, Inc. - Iproteos S.L. - Jeil Pharmaceutical Co., Ltd. - KineMed, Inc. - Medeia Therapeutics Ltd. - Motac Neuroscience Ltd - Netherlands Translational Research Center B.V. - nLife Therapeutics, S.L. - Novartis AG - OPKO Health, Inc. - Orion Oyj - Peptron, Inc. - Pfizer Inc. - QR Pharma, Inc. - QRxPharma Limited - Raptor Pharmaceuticals Corp. - SanBio, Inc. - Saneron CCEL Therapeutics, Inc. - Stelic Institute & Co. - Sumitomo Dainippon Pharma Co., Ltd. For more information visit http://www.researchandmarkets.com/research/7k9xvt/parkinsons
RPTP: 8.44 (+0.22), KNMD: (), OPK: 8.18 (-0.11), PFE: 30.95 (-0.70), AZN: 71.80 (-1.80), GSK: 42.42 (-0.93), FOLD: 8.15 (+0.18), NVS: 93.52 (-0.82)
Raptor Pharmaceutical awards inducement grants to seven new employees under NASDAQ Listing Rule 5635(c) (4)
M2 - Tue Dec 02, 5:32AM CST
Biopharmaceutical company Raptor Pharmaceutical (NasdaqGM:RPTP) said on Monday that its board of directors has announced inducement stock option awards to seven new employees on 25 November 2014.
RPTP: 8.44 (+0.22)
Raptor Pharmaceutical Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
GlobeNewswire - Mon Dec 01, 8:09AM CST
Raptor Pharmaceutical Corp. (Nasdaq:RPTP) today announced that on November 25, 2014, as a key requirement of the Company's strategy of strengthening its leadership team and employee base, continuing the expansion of its commercial activities into new territories, and increasing the expansion of its product development programs, the board of directors approved inducement stock option awards to new hire employees pursuant to the Raptor Pharmaceutical Corp. 2014 Employment Commencement Stock Incentive Plan. The plan was approved by the board of directors under Rule 5635(c)(4) of the Nasdaq Global Select Market for equity grants to induce new employees to enter into employment with the Company. The grants consisted of stock options to purchase an aggregate of 217,288 shares of the Company's common stock to six new employees and an option to purchase 165,000 shares to David Happel, the Company's new Chief Commercial Officer, each with a per share exercise price of $9.92, the closing price on the trading date immediately prior to the grant date.
RPTP: 8.44 (+0.22)
Insider Trading Alert - RPTP, TEAR And ISRG Traded By Insiders
at The Street - Wed Nov 26, 10:59AM CST
Stocks with insider trader activity include RPTP, TEAR and ISRG
ISRG: 502.77 (-3.35), TEAR: 2.39 (+0.02), RPTP: 8.44 (+0.22)
Raptor Pharmaceutical to Present at the 26th Annual Piper Jaffray Healthcare Conference
GlobeNewswire - Tue Nov 18, 3:10PM CST
Raptor Pharmaceutical Corp. (Nasdaq:RPTP) today announced that the company will participate in the following conference:
RPTP: 8.44 (+0.22)
Global Huntington's Disease Therapeutics Market 2014-2018 - Novel Mechanisms Targeted by Pipeline Candidates
M2 - Tue Nov 11, 5:15AM CST
Research and Markets (http://www.researchandmarkets.com/research/lbsc46/global) has announced the addition of the "Global Huntington's Disease Therapeutics Market 2014-2018" report to their offering. The Global Huntington's Disease Therapeutics market to grow at a CAGR of 29.46 percent over the period 2013-2018. Huntington's disease is a progressive neurodegenerative disorder that can be inherited from one generation to another as an autosomal dominant trait. It arises due to genetically programmed degeneration of neurons in some parts of the brain such as basal ganglia and cerebral cortex. Basal ganglia plays an important role in coordinating movement while cerebral cortex regulates perception, thought, and memory. Degeneration of neurons leads to progressive cognitive impairment and dementia. One key trend emerging in this market is the targeting of novel mechanisms by pipeline molecules. Drugs with novel mechanisms might prove to be better treatment options and might affect the course of the disease through their neuroprotective effects. According to the report, one of the major drivers of the market is the unmet medical needs such as the lack of safe, efficacious, and disease-modifying treatments with regard to the treatment of Huntington's disease. Any drug that can cater to these needs is expected to drive the market during the forecast period. Further, the report states that the poor diagnosis rate is one of the major challenges in this market. This delays the initiation of therapy and affects the quality of life of the patient. Key Vendors - Lundbeck - Valeant Pharmaceuticals International Other Prominent Vendors - Auspex Pharmaceuticals - GlaxoSmithKline - Ipsen - Omeros - Palobiofarma - Pfizer - Prana Biotechnology - Raptor Pharmaceutical - Siena Biotech - SOM Biotech - Teva Pharmaceutical Industries Key Topics Covered: - Executive Summary - List of Abbreviations - Scope of the Report - Market Research Methodology - Introduction - Prevalence of Huntington's Disease - Market Landscape - Market Segmentation by Drug Class - Geographical Segmentation - Buying Criteria - Market Growth Drivers - Drivers and their Impact - Market Challenges - Impact of Drivers and Challenges - Market Trends - Trends and their Impact - Vendor Landscape - Clinical-stage Pipeline Candidates - Key Information of Clinical-stage Pipeline Candidates - Discontinued Clinical-stage Pipeline Drugs - Key Vendor Analysis For more information visit http://www.researchandmarkets.com/research/lbsc46/global
RPTP: 8.44 (+0.22), TEVA: 55.92 (-0.92), ASPX: 24.90 (+0.64), GSK: 42.42 (-0.93), PRAN: 1.86 (-0.05), VRX.TO: 160.64 (+0.46)
Raptor Pharmaceutical's (RPTP) CEO Chris Starr on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Thu Nov 06, 8:58PM CST
RPTP: 8.44 (+0.22)
Raptor Pharmaceutical tops Street 3Q forecasts
Automated Insights - Thu Nov 06, 5:18PM CST
NOVATO, Calif. (AP) _ Raptor Pharmaceutical Corp. (RPTP) on Thursday reported a loss of $6 million in its third quarter.
RPTP: 8.44 (+0.22)
Raptor Pharmaceutical beats on revenue
Seeking Alpha - at Seeking Alpha - Thu Nov 06, 4:29PM CST
RPTP: 8.44 (+0.22)
Raptor Pharmaceutical Reports Third Quarter 2014 Financial Results and Provides Corporate Update
GlobeNewswire - Thu Nov 06, 3:20PM CST
Global Net Product Sales for PROCYSBI of $23.8 Million for Third Quarter 2014
RPTP: 8.44 (+0.22)
Raptor Pharmaceutical to Hold Third Quarter 2014 Financial Results Conference Call and Webcast on Thursday, November 6, at 4:30 p.m. ET
GlobeNewswire - Wed Oct 29, 3:12PM CDT
Raptor Pharmaceutical Corp. (Nasdaq:RPTP) today announced that the company will release third quarter 2014 financial results on Thursday, November 6, 2014 after market close. Management will conduct a conference call and live audio webcast at 4:30 p.m. ET (1:30 p.m. PT) that day to discuss the financial results and provide a corporate update.
RPTP: 8.44 (+0.22)
Raptor Pharmaceutical Announces Management Changes
GlobeNewswire - Thu Oct 23, 6:30AM CDT
Raptor Pharmaceutical Corp. (Nasdaq:RPTP) today announced that it has strengthened its leadership team with the hiring of two new executives: David Happel, Chief Commercial Officer, who will oversee Raptor's global commercial operations, and Kimberly Lee, D.O., Vice President, Corporate Strategy and Communications, who will lead strategy development, investor relations and media communications.
RPTP: 8.44 (+0.22)
Today's Weak On High Volume Stock: Raptor Pharmaceutical (RPTP)
at The Street - Tue Oct 07, 9:00AM CDT
Trade-Ideas LLC identified Raptor Pharmaceutical (RPTP) as a weak on high relative volume candidate
RPTP: 8.44 (+0.22)
Raptor Pharmaceuticals (RPTP) Crumbles: Stock Falls by 7.2% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Sep 30, 7:36AM CDT
Raptor Pharmaceuticals (RPTP) fell over 7% in the last trading session amid huge volumes, continuing its recent trend, as the stock is now down over 11% since Sep 11.
CBM: 23.66 (+0.24), RPTP: 8.44 (+0.22), GILD: 104.13 (-0.18), PDLI: 7.41 (-0.08)
Biotech Stocks Technical Insight - Incyte, Regado Biosciences, ACADIA Pharma, Pharmacyclics, and Raptor Pharma
PR Newswire - Fri Sep 26, 7:45AM CDT
The US markets on Thursday, September 25, 2014, declined with the Dow Jones Industrial Average finishing at 16,945.80, down 1.54% and the NASDAQ Composite closing at 4,466.75, down 1.94%. The S&P 500 ended the session 1.62% lower at 1,965.99. During the trading session, all the ten sectors finished on a negative note. The S&P 500 Health Care Sector Index closed the day at 743.47, down 1.58%, whereas the index has advanced 4.99% in the previous three months. Investor-Edge has initiated coverage on the following equities: Incyte Corporation (NASDAQ: INCY), Regado Biosciences Inc. (NASDAQ: RGDO), ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), Pharmacyclics Inc. (NASDAQ: PCYC), and Raptor Pharmaceutical Corporation (NASDAQ: RPTP). Free research on these five companies can be accessed at:
ACAD: 32.53 (-0.10), PCYC: 132.65 (-2.34), RPTP: 8.44 (+0.22), INCY: 74.65 (-1.27), RGDO: 0.89 (+0.02)
Raptor Pharmaceutical to Present at Leerink Rare Disease Roundtable
GlobeNewswire - Tue Sep 23, 7:00AM CDT
Raptor Pharmaceutical Corp. (Nasdaq:RPTP) today announced that company management will present at the Leerink Rare Disease Roundtable in New York on Wednesday, October 1, 2014 at 1:30 p.m. EDT/10:30 a.m. PDT. A live audio webcast and archive of the presentation will be available on the company website at www.raptorpharma.com.
RPTP: 8.44 (+0.22)
TBF, ANF, IDG, NYMT, MSZ, RPTP Are Seasonally Ripe To Go Down In the Next Five Weeks
M2 - Wed Sep 17, 4:03AM CDT
BUYINS.NET / www.squeezetrigger.com is monitoring the Seasonality of ProShares Short 20+ Yr Treasury (NYSE:TBF), ABERCROMBIE & FITCH CO (NYSE:ANF), Indigo Books and Music Inc (NYSE:IDG), New York Mortgage Trust Inc (NASDAQ:NYMT), MORGAN STANLEY CAPITAL TRUST VII (NYSE:MSZ), Raptor Pharmaceutical Corp (NASDAQ:RPTP) and each have a high seasonal probability to go Down in the next weeks. By identifying stocks that are poised to go up or down based on seasonal tendencies, traders can increase their odds of making money. SqueezeTrigger.com is able to analyze over 20 years of data in less than 1 second for any stock in the market and determine if the stock has a long or short seasonal bias, how many trading days the move is expected to last, the probability of that move and the percentage move the stock is expected to make based on the seasonal bias. The technology used to generate these predictions is available for a low monthly fee at:
IDG: 25.80 (-0.08), TBF: 25.21 (-0.40), RPTP: 8.44 (+0.22), MSZ: 25.46 (-0.01), ANF: 27.76 (+0.46), NYMT: 7.82 (-0.08), MS: 36.25 (-1.15)
Raptor Pharmaceutical to Present at Upcoming Investor Conference in September
GlobeNewswire - Wed Aug 27, 7:00AM CDT
Raptor Pharmaceutical Corp. (Nasdaq:RPTP) today announced that company management will present at the Morgan Stanley Global Healthcare Conference in New York on Wednesday, September 10, 2014 at 11:30 a.m. EDT/8:30 a.m. PDT. A live audio webcast and archive of the presentation will be available on the company website at www.raptorpharma.com.
RPTP: 8.44 (+0.22)
Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline Review, H2 2014
M2 - Mon Dec 08, 3:23AM CST
Research and Markets (http://www.researchandmarkets.com/research/48lh7t/non_alcoholic) has announced the addition of the "Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Non Alcoholic Fatty Liver Disease (NAFLD), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Non Alcoholic Fatty Liver Disease (NAFLD) and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Non Alcoholic Fatty Liver Disease (NAFLD) - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Non Alcoholic Fatty Liver Disease (NAFLD) pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope Companies Mentioned: - F. Hoffmann-La Roche - Merck & Co - Novartis - Daewoong Pharmaceutical - Orchid Chemicals & Pharmaceuticals - Phynova Group - Raptor Pharmaceuticals - Phenex Pharmaceuticals - Metabolic Solutions Development - Zafgen - Verva Pharmaceuticals - Galmed International - TCM Biotech International For more information visit http://www.researchandmarkets.com/research/48..._alcoholic
RPTP: 8.44 (+0.22), MRK: 57.72 (-1.62), NVS: 93.52 (-0.82)
Raptor Pharmaceutical Corp. Is An Investment With Significant Upside IN 2015
Clinically Sound Investor - at Seeking Alpha - Thu Dec 04, 8:57AM CST
RPTP: 8.44 (+0.22)
Parkinson's Disease - Pipeline Review, H2 2014
M2 - Tue Dec 02, 5:55AM CST
Research and Markets (http://www.researchandmarkets.com/research/7k9xvt/parkinsons) has announced the addition of the "Parkinson's Disease - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Parkinson's Disease, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Parkinson's Disease - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Parkinson's Disease pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: 169 companies are cited in this text including: - Amicus Therapeutics, Inc. - AstraZeneca PLC - Bial - Portela & Ca, S.A. - Calico LLC - Cardax Pharmaceuticals, Inc. - Edison Pharmaceuticals, Inc. - GlaxoSmithKline plc - GliaCure Inc. - H. Lundbeck A/S - Io Therapeutics, Inc. - Iproteos S.L. - Jeil Pharmaceutical Co., Ltd. - KineMed, Inc. - Medeia Therapeutics Ltd. - Motac Neuroscience Ltd - Netherlands Translational Research Center B.V. - nLife Therapeutics, S.L. - Novartis AG - OPKO Health, Inc. - Orion Oyj - Peptron, Inc. - Pfizer Inc. - QR Pharma, Inc. - QRxPharma Limited - Raptor Pharmaceuticals Corp. - SanBio, Inc. - Saneron CCEL Therapeutics, Inc. - Stelic Institute & Co. - Sumitomo Dainippon Pharma Co., Ltd. For more information visit http://www.researchandmarkets.com/research/7k9xvt/parkinsons
RPTP: 8.44 (+0.22), KNMD: (), OPK: 8.18 (-0.11), PFE: 30.95 (-0.70), AZN: 71.80 (-1.80), GSK: 42.42 (-0.93), FOLD: 8.15 (+0.18), NVS: 93.52 (-0.82)
Raptor Pharmaceutical awards inducement grants to seven new employees under NASDAQ Listing Rule 5635(c) (4)
M2 - Tue Dec 02, 5:32AM CST
Biopharmaceutical company Raptor Pharmaceutical (NasdaqGM:RPTP) said on Monday that its board of directors has announced inducement stock option awards to seven new employees on 25 November 2014.
RPTP: 8.44 (+0.22)
Raptor Pharmaceutical Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
GlobeNewswire - Mon Dec 01, 8:09AM CST
Raptor Pharmaceutical Corp. (Nasdaq:RPTP) today announced that on November 25, 2014, as a key requirement of the Company's strategy of strengthening its leadership team and employee base, continuing the expansion of its commercial activities into new territories, and increasing the expansion of its product development programs, the board of directors approved inducement stock option awards to new hire employees pursuant to the Raptor Pharmaceutical Corp. 2014 Employment Commencement Stock Incentive Plan. The plan was approved by the board of directors under Rule 5635(c)(4) of the Nasdaq Global Select Market for equity grants to induce new employees to enter into employment with the Company. The grants consisted of stock options to purchase an aggregate of 217,288 shares of the Company's common stock to six new employees and an option to purchase 165,000 shares to David Happel, the Company's new Chief Commercial Officer, each with a per share exercise price of $9.92, the closing price on the trading date immediately prior to the grant date.
RPTP: 8.44 (+0.22)
Insider Trading Alert - RPTP, TEAR And ISRG Traded By Insiders
at The Street - Wed Nov 26, 10:59AM CST
Stocks with insider trader activity include RPTP, TEAR and ISRG
ISRG: 502.77 (-3.35), TEAR: 2.39 (+0.02), RPTP: 8.44 (+0.22)
Raptor Pharmaceutical to Present at the 26th Annual Piper Jaffray Healthcare Conference
GlobeNewswire - Tue Nov 18, 3:10PM CST
Raptor Pharmaceutical Corp. (Nasdaq:RPTP) today announced that the company will participate in the following conference:
RPTP: 8.44 (+0.22)
Global Huntington's Disease Therapeutics Market 2014-2018 - Novel Mechanisms Targeted by Pipeline Candidates
M2 - Tue Nov 11, 5:15AM CST
Research and Markets (http://www.researchandmarkets.com/research/lbsc46/global) has announced the addition of the "Global Huntington's Disease Therapeutics Market 2014-2018" report to their offering. The Global Huntington's Disease Therapeutics market to grow at a CAGR of 29.46 percent over the period 2013-2018. Huntington's disease is a progressive neurodegenerative disorder that can be inherited from one generation to another as an autosomal dominant trait. It arises due to genetically programmed degeneration of neurons in some parts of the brain such as basal ganglia and cerebral cortex. Basal ganglia plays an important role in coordinating movement while cerebral cortex regulates perception, thought, and memory. Degeneration of neurons leads to progressive cognitive impairment and dementia. One key trend emerging in this market is the targeting of novel mechanisms by pipeline molecules. Drugs with novel mechanisms might prove to be better treatment options and might affect the course of the disease through their neuroprotective effects. According to the report, one of the major drivers of the market is the unmet medical needs such as the lack of safe, efficacious, and disease-modifying treatments with regard to the treatment of Huntington's disease. Any drug that can cater to these needs is expected to drive the market during the forecast period. Further, the report states that the poor diagnosis rate is one of the major challenges in this market. This delays the initiation of therapy and affects the quality of life of the patient. Key Vendors - Lundbeck - Valeant Pharmaceuticals International Other Prominent Vendors - Auspex Pharmaceuticals - GlaxoSmithKline - Ipsen - Omeros - Palobiofarma - Pfizer - Prana Biotechnology - Raptor Pharmaceutical - Siena Biotech - SOM Biotech - Teva Pharmaceutical Industries Key Topics Covered: - Executive Summary - List of Abbreviations - Scope of the Report - Market Research Methodology - Introduction - Prevalence of Huntington's Disease - Market Landscape - Market Segmentation by Drug Class - Geographical Segmentation - Buying Criteria - Market Growth Drivers - Drivers and their Impact - Market Challenges - Impact of Drivers and Challenges - Market Trends - Trends and their Impact - Vendor Landscape - Clinical-stage Pipeline Candidates - Key Information of Clinical-stage Pipeline Candidates - Discontinued Clinical-stage Pipeline Drugs - Key Vendor Analysis For more information visit http://www.researchandmarkets.com/research/lbsc46/global
RPTP: 8.44 (+0.22), TEVA: 55.92 (-0.92), ASPX: 24.90 (+0.64), GSK: 42.42 (-0.93), PRAN: 1.86 (-0.05), VRX.TO: 160.64 (+0.46)
Raptor Pharmaceutical's (RPTP) CEO Chris Starr on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Thu Nov 06, 8:58PM CST
RPTP: 8.44 (+0.22)
Raptor Pharmaceutical tops Street 3Q forecasts
Automated Insights - Thu Nov 06, 5:18PM CST
NOVATO, Calif. (AP) _ Raptor Pharmaceutical Corp. (RPTP) on Thursday reported a loss of $6 million in its third quarter.
RPTP: 8.44 (+0.22)
Raptor Pharmaceutical beats on revenue
Seeking Alpha - at Seeking Alpha - Thu Nov 06, 4:29PM CST
RPTP: 8.44 (+0.22)
Raptor Pharmaceutical Reports Third Quarter 2014 Financial Results and Provides Corporate Update
GlobeNewswire - Thu Nov 06, 3:20PM CST
Global Net Product Sales for PROCYSBI of $23.8 Million for Third Quarter 2014
RPTP: 8.44 (+0.22)
Raptor Pharmaceutical to Hold Third Quarter 2014 Financial Results Conference Call and Webcast on Thursday, November 6, at 4:30 p.m. ET
GlobeNewswire - Wed Oct 29, 3:12PM CDT
Raptor Pharmaceutical Corp. (Nasdaq:RPTP) today announced that the company will release third quarter 2014 financial results on Thursday, November 6, 2014 after market close. Management will conduct a conference call and live audio webcast at 4:30 p.m. ET (1:30 p.m. PT) that day to discuss the financial results and provide a corporate update.
RPTP: 8.44 (+0.22)
Raptor Pharmaceutical Announces Management Changes
GlobeNewswire - Thu Oct 23, 6:30AM CDT
Raptor Pharmaceutical Corp. (Nasdaq:RPTP) today announced that it has strengthened its leadership team with the hiring of two new executives: David Happel, Chief Commercial Officer, who will oversee Raptor's global commercial operations, and Kimberly Lee, D.O., Vice President, Corporate Strategy and Communications, who will lead strategy development, investor relations and media communications.
RPTP: 8.44 (+0.22)
Today's Weak On High Volume Stock: Raptor Pharmaceutical (RPTP)
at The Street - Tue Oct 07, 9:00AM CDT
Trade-Ideas LLC identified Raptor Pharmaceutical (RPTP) as a weak on high relative volume candidate
RPTP: 8.44 (+0.22)
Raptor Pharmaceuticals (RPTP) Crumbles: Stock Falls by 7.2% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Sep 30, 7:36AM CDT
Raptor Pharmaceuticals (RPTP) fell over 7% in the last trading session amid huge volumes, continuing its recent trend, as the stock is now down over 11% since Sep 11.
CBM: 23.66 (+0.24), RPTP: 8.44 (+0.22), GILD: 104.13 (-0.18), PDLI: 7.41 (-0.08)
Biotech Stocks Technical Insight - Incyte, Regado Biosciences, ACADIA Pharma, Pharmacyclics, and Raptor Pharma
PR Newswire - Fri Sep 26, 7:45AM CDT
The US markets on Thursday, September 25, 2014, declined with the Dow Jones Industrial Average finishing at 16,945.80, down 1.54% and the NASDAQ Composite closing at 4,466.75, down 1.94%. The S&P 500 ended the session 1.62% lower at 1,965.99. During the trading session, all the ten sectors finished on a negative note. The S&P 500 Health Care Sector Index closed the day at 743.47, down 1.58%, whereas the index has advanced 4.99% in the previous three months. Investor-Edge has initiated coverage on the following equities: Incyte Corporation (NASDAQ: INCY), Regado Biosciences Inc. (NASDAQ: RGDO), ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), Pharmacyclics Inc. (NASDAQ: PCYC), and Raptor Pharmaceutical Corporation (NASDAQ: RPTP). Free research on these five companies can be accessed at:
ACAD: 32.53 (-0.10), PCYC: 132.65 (-2.34), RPTP: 8.44 (+0.22), INCY: 74.65 (-1.27), RGDO: 0.89 (+0.02)
Raptor Pharmaceutical to Present at Leerink Rare Disease Roundtable
GlobeNewswire - Tue Sep 23, 7:00AM CDT
Raptor Pharmaceutical Corp. (Nasdaq:RPTP) today announced that company management will present at the Leerink Rare Disease Roundtable in New York on Wednesday, October 1, 2014 at 1:30 p.m. EDT/10:30 a.m. PDT. A live audio webcast and archive of the presentation will be available on the company website at www.raptorpharma.com.
RPTP: 8.44 (+0.22)
TBF, ANF, IDG, NYMT, MSZ, RPTP Are Seasonally Ripe To Go Down In the Next Five Weeks
M2 - Wed Sep 17, 4:03AM CDT
BUYINS.NET / www.squeezetrigger.com is monitoring the Seasonality of ProShares Short 20+ Yr Treasury (NYSE:TBF), ABERCROMBIE & FITCH CO (NYSE:ANF), Indigo Books and Music Inc (NYSE:IDG), New York Mortgage Trust Inc (NASDAQ:NYMT), MORGAN STANLEY CAPITAL TRUST VII (NYSE:MSZ), Raptor Pharmaceutical Corp (NASDAQ:RPTP) and each have a high seasonal probability to go Down in the next weeks. By identifying stocks that are poised to go up or down based on seasonal tendencies, traders can increase their odds of making money. SqueezeTrigger.com is able to analyze over 20 years of data in less than 1 second for any stock in the market and determine if the stock has a long or short seasonal bias, how many trading days the move is expected to last, the probability of that move and the percentage move the stock is expected to make based on the seasonal bias. The technology used to generate these predictions is available for a low monthly fee at:
IDG: 25.80 (-0.08), TBF: 25.21 (-0.40), RPTP: 8.44 (+0.22), MSZ: 25.46 (-0.01), ANF: 27.76 (+0.46), NYMT: 7.82 (-0.08), MS: 36.25 (-1.15)
Raptor Pharmaceutical to Present at Upcoming Investor Conference in September
GlobeNewswire - Wed Aug 27, 7:00AM CDT
Raptor Pharmaceutical Corp. (Nasdaq:RPTP) today announced that company management will present at the Morgan Stanley Global Healthcare Conference in New York on Wednesday, September 10, 2014 at 11:30 a.m. EDT/8:30 a.m. PDT. A live audio webcast and archive of the presentation will be available on the company website at www.raptorpharma.com.
RPTP: 8.44 (+0.22)
